---
run_id: halo-evidence-vs-diagnosis-validation-v12-generic-advice-prompted-01
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: generic_advice_prompted
run_number: 1
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 105
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
condition_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
output_file: model-outputs/generic_advice_prompted.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 01)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `generic_advice_prompted`, run 1 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 105, on the frozen condition packet.

## Output

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Trade-offs
You are currently experiencing a "false positive" signal. Your executive team is attributing commercial success to product value, but the evidence suggests that success is actually driven by **sales incentives** (bundle pricing) and **roadmap promises** (future-state pitching).

The most dangerous risk you face is "phantom adoption." Usage is up 39%, but the data shows this is driven by managers using it for training/enablement, not analysts using it for production. The "silent churn" from regional administrators and the abandonment in the public sector suggest that while PlanPilot is *interesting* to buyers, it may not be *useful* to the actual practitioners.

Here is why the Case Evidence Review is the superior choice over the others:

1.  **Against the Adoption Quality Sprint:** This measures *quantity* of activity (return rates), not *quality* of outcome. If analysts are returning to the tool only because their managers force them to, your dashboard will look green while your churn risk remains red.
2.  **Against the Demand Cleanroom:** This is a high-risk move 12 days before a budget lock. If the cleanroom results are negative, you have effectively killed your expansion momentum without knowing *why* the product is failing. It tells you if people will pay, but not how to fix the tool so they *want* to pay.
3.  **Against Scaling Broadly:** This is the "trap" option. Scaling a product that analysts cannot explain to reviewers (especially in public sector) will accelerate churn and damage your reputation for "commercial discipline."
4.  **Against Narrowing to Public Sector:** This is premature. You don't yet know if the public sector failure is due to a fundamental product flaw or a specific compliance/explanation gap.

The **Case Evidence Review** is the only option that solves the "black box" problem. By looking at whether suggestions were accepted, overridden, or rewritten, you move from *proxy metrics* (usage logs) to *truth metrics* (work product). You will discover if PlanPilot is actually solving the workflow problem or if it is simply a "drafting tool" that requires so much manual correction that it doesn't actually save time.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is **slow and qualitative**. Unlike the Adoption Quality Sprint, it does not provide a real-time dashboard for the board. It requires manual effort from account managers and customers, and it may produce "messy" data that contradicts the current optimistic narrative. You are choosing a rigorous, slow truth over a fast, convenient illusion, which may be politically difficult given the current mood of the executive team.

### Evidence That Would Change My Mind
I would switch my recommendation to the **Demand Cleanroom** if you discover that your "bundle pricing" accounts represent more than 50% of your total expansion revenue.

If the commercial success is almost entirely artificial (driven by price discounts rather than perceived value), you no longer have a "product-market fit" question—you have a "pricing and packaging" crisis. In that specific scenario, you must immediately stop the bleeding and test true willingness-to-pay via the Cleanroom before committing any more engineering resources to the feature.
